August 9, 2018 The Lupus Research Alliance appreciates new published findings that finally document what we and the lupus community have long known only too well – lupus is a leading cause of death among women, particularly threatening the lives of our most vulnerable – children and teens. These findings propel our determination to provide […] READ MORE
August 2, 2018 Inflammation helps us repair injuries and defeat infections. It’s supposed to shut down once a crisis is over. In people with lupus, however, inflammation persists and can damage the joints, skin, and organs. Researchers have discovered a molecular sensor in cells known as the NLRP3 inflammasome that triggers inflammation. When the inflammasome […] READ MORE
Posted July 23, 2018 in New York Times We at the Lupus Research Alliance extend our deepest condolences to the family of Jean Steinberg. She and her late husband Meyer “Mike” along with their entire family have been long-time supporters of our lupus cause, determined to fund the most promising research that can better treat […] READ MORE
July 26, 2018 By uncovering how some killer viruses beat our immune system, scientists partly funded by the Lupus Research Alliance have identified a potential new way to treat lupus. The viruses that cause Lassa fever and other similar diseases kill thousands of people every year. One reason these viruses are deadly is that they […] READ MORE
July 17, 2018 The Lupus Research Alliance New York City Lupus Research Reception featured incredible speakers whose remarks are well worth sharing: Larry Schreiber, President of Empire BlueCross BlueShield; Meggan Mackay, MD, MS, Investigator at the Feinstein Institute for Medical Research; and Kenneth Farber, President & CEO, Lupus Research Alliance. The take-aways are clear – companies fund causes […] READ MORE
July 16, 2018. The Lupus Research Alliance is pleased and very encouraged to share a promising scientific breakthrough reported in the New York Times with real potential to revolutionize lupus treatment. Just reported in the prestigious journal Nature, scientists in Dr. Alexander Marson’s lab at the University of California, San Francisco have developed an innovative […] READ MORE
July 12, 2018 With funding from our most competitive grant Dr. Zhijian “James” Chen, Professor of Molecular Biology at UT Southwestern, discovered a mechanism that stimulates the immune system which could lead to novel treatments for infections, lupus and other autoimmune diseases and cancer. Dr. Chen’s discovery of an enzyme cGAS uncovered an essential process that […] READ MORE
July 3, 2018 The Lupus Research Alliance, Antidote, and SCORR Marketing are conducting a survey to learn what people with lupus and their caregivers, or care partners, think about clinical research. Survey participation will take about 20 minutes and your answers are confidential. By answering these questions, you can help us make clinical trials easier for people willing to participate. […] READ MORE
The 2018 Lupus Insight Prize was awarded on June 21, 2018 to Betty Diamond, MD, Professor & Head, Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research for her groundbreaking work in lupus nephritis. Through the Lupus Insight Prize, the Lupus Research Alliance awards $100,000 in recognition of major insights and […] READ MORE
June 28, 2018 With an overwhelming majority vote of 359 to 49, the House of Representatives just passed a bill to allocate $5 million to the Defense Department’s Congressionally Directed Medical Research Program for lupus in the 2019 budget. This federal support of lupus research is a result of advocacy by lupus patients, organizations like […] READ MORE
June 27, 2018 This new issue of the Lupus Research Update (LRU) takes you behind the scenes of some of the most groundbreaking research and how the Lupus Research Alliance raises the funds that enable diverse and accomplished scientists to pioneer new studies in the field. Featured in this LRU, Penn State researcher Dr. Laura […] READ MORE
June 19, 2018 Once-daily oral baricitinib 4 mg was associated with significant clinical improvements compared with placebo in patients with systemic lupus erythematosus (SLE) receiving standard background therapy, according to data presented at the European League Against Rheumatism (EULAR) Congress held in Amsterdam, June 13 to 16, 2018…. A significantly greater percentage of patients in the […] READ MORE
